Radiopharmaceuticals Startup RayzeBio Seeks Public Debut After Raising $400M From Investors
Radiopharmaceuticals Startup RayzeBio Seeks Public Debut After Raising $400M From Investors
RayzeBio Inc, a San Diego company focused on radiopharmaceutical therapies for cancer, filed on Thursday to raise up to $100 million in an initial public offering.
RayzeBio Inc.是一家總部位於聖地亞哥的公司，專注於癌症的放射性藥物療法。該公司週四申請在首次公開募股(IPO)中籌集至多1億美元。
The phase 3-stage company was founded in 2020 and plans to list on the Nasdaq under the symbol RYZB.
三期公司成立於2020年，計劃在納斯達克上市，股票代碼為RYZB。
The company's lead candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225 (Ac225), to tumors overexpressing somatostatin receptor (SSTR).
該公司的主要候選藥物RYZ101旨在為過度表達生長抑素受體(SSTR)的腫瘤提供一種高效的阿爾法粒子放射性同位素Actina 225(Ac225)。
RayzeBio says that a radiopharmaceutical therapeutic (RPT) utilizing Ac225 has the potential to provide greater efficacy over approved beta particle radioisotope Lutetium 177, or Lu177, therapies.
RayzeBio表示，使用Ac225的放射性藥物療法(RPT)有可能提供比已批准的貝塔粒子放射性同位素Lu177或Lu177療法更好的療效。
Alpha particles can deliver up to 400 times higher energy than beta particles, leading to double-stranded DNA breaks, lethal to cancer cells.
阿爾法粒子可以提供比貝塔粒子高400倍的能量，導致雙鏈DNA斷裂，對癌細胞致命。
The company started a phase 3 trial of the lead candidate RYZ101 for gastroenteropancreatic neuroendocrine tumors in May.
該公司於5月份開始了胃腸胰腺神經內分泌腫瘤的主要候選藥物RYZ101的3期試驗。
The candidate is also being tested in a phase 1 study of SSTR-expressing extensive-stage small-cell lung cancer patients.
該候選藥物還在表達SSTR的廣泛期小細胞肺癌患者的1期研究中進行測試。
In its filing, RayzeBio described its hopes for RYZ101 to become a "pipeline-in-a-product" that could be used for other SSTR2-expressing cancers.
在ITS中歸檔，RayzeBio描述了它希望RYZ101成為一種“產品中的流水線”，可以用於其他表達SSTR2的癌症。
The IPO proceeds will also be funneled toward developing RYZ801 and RYZ811, two GPC3-targeting radiopharmaceuticals gearing up for phase 1 trials in hepatocellular carcinoma.
IPO募集的資金還將用於開發RYZ801和RYZ811，這兩種靶向GPC3的放射性藥物正在為肝細胞癌的第一階段試驗做準備。
The company plans to file for an IND for each candidate in 1H of 2024.
該公司計劃在2024年上半年為每位候選人申請IND。
The company has secured $418 million in funding from a group of premier life science investors, including venBio Partners, Venrock Healthcare Capital Partners, Versant Ventures, and Viking Global Investors.
該公司已經從一群頂級生命科學投資者那裡獲得了4.18億美元的資金，其中包括venBio Partners、VenRock Healthcare Capital Partners、Versant Ventures和Viking Global Investors。
譯文內容由第三人軟體翻譯。